Spijkers-Hagelstein et al. (2013) were able to show that to improve the treatment success of glucocorticoid therapy in ALL, phosphorylation of annexin A2 is required; additionally, this phosphorylation requires S100A10 expression and the absence of both annexin A2 and S100A10 reduces the resistance to treatment in the ALL SEM cell line [96]. Here, ANXA2 is linked to acute lymphoblastic leukemia.